Confluence Announces $4 Million in Series A Financing  
9/17/2012 10:00:00 AM

ST. LOUIS--(BUSINESS WIRE)--Confluence Life Sciences, Inc., a biotechnology company focused on the rapid discovery and development of kinase inhibitors to treat cancer and inflammatory disease, today announced a $4 million Series A venture capital financing. Proceeds from the financing will enable Confluence to advance its product candidates and leverage its proprietary technology platform to discover and develop novel therapeutics.